This volume of Pharmaceutical Biocatalysis starts with a discussion on the importance of
biocatalytic synthesis approaches for a sustainable and environmentally friendly production …

In the last few years we have witnessed a vast expansion of our knowledge regarding the
molecular and genetic profile of gastric cancer. The molecular subtypes described have …

Current chemotherapies for oesophageal cancer display poor efficacy and tolerability,
highlighting an unmet need for novel chemotherapeutic agents. Artemisinin derivatives …

El cáncer gástrico (CG) es la tercera causa de muerte por cáncer en todo el mundo; tanto
los factores ambientales como los genéticos están implicados en la etiología de esta …

Gastric cancer is one of the most frequently diagnosed cancers worldwide, with a relative 5
year survival of 27.7%. The clinical outcome for advanced gastric cancer remains poor, with …

The incidence of esophageal adenocarcinoma (AC) is rapidly rising in Western countries
whereas the incidence of esophageal squamous cell carcinoma (SCC) is fairly stable …

Esophageal cancer is the sixth leading causes of cancer mortality worldwide (1). In North
America, adenocarcinoma has become the most common histology whereas squamous …

In the past decades, survival improvement was overall modest with conventional
chemotherapy regimens, and 2-year survival rate did not exceed the 20%. Presently, phase …

Gastric cancer (GC) is the third leading cause of cancer death worldwide; both
environmental and genetic factors are involved in the etiology of this neoplasia. The human …

Abstract Development of therapeutic resistance limits the efficacy of current cancer
treatment. Understanding the molecular basis for therapeutic resistance should facilitate the …